Home » Stocks » Quidel Corporation

Quidel Corporation (QDEL)

Stock Price: $272.76 USD -12.59 (-4.41%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $275.25 +2.49 (0.91%) Aug 7, 7:47 PM

Stock Price Chart

Key Info

Market Cap 11.44B
Revenue (ttm) 655.08M
Net Income (ttm) 154.70M
Shares Out 41.95M
EPS (ttm) 3.55
PE Ratio 76.83
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $272.76
Previous Close $285.35
Change ($) -12.59
Change (%) -4.41%
Day's Open 288.00
Day's Range 269.24 - 292.95
Day's Volume 713,417
52-Week Range 54.13 - 306.72

More Stats

Market Cap 11.44B
Enterprise Value 11.51B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 41.95M
Float 38.08M
EPS (basic) 3.7
EPS (diluted) 3.55
FCF / Share 3.62
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.30%
FCF Yield 1.33%
Payout Ratio n/a
Shares Short 2.68M
Short Ratio 1.44
Short % of Float 8.96%
Beta 1.16
PE Ratio 76.83
Forward PE n/a
P/FCF Ratio 75.08
PS Ratio 17.47
PB Ratio 19.57
Revenue 655.08M
Operating Income 191.04M
Net Income 154.70M
Free Cash Flow 152.40M
Net Cash -64.08M
Net Cash / Share -1.53
Gross Margin 48.97%
Operating Margin 29.16%
Profit Margin 23.60%
FCF Margin 23.26%
ROA 13.96%
ROE 27.58%
ROIC 53.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$264.75*
(-2.94% downside)
Low
160
Current: $272.76
High
363
Target: 264.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue535522278192196184177156159113
Revenue Growth2.41%88.05%44.96%-2.31%6.5%3.85%13.86%-1.8%39.94%-
Gross Profit32131615611211811011094.4695.7460.73
Operating Income92.7295.939.55-4.442.74-9.214.849.6913.74-15.29
Net Income72.9274.18-8.17-13.81-6.08-7.077.394.997.63-11.27
Shares Outstanding40.8638.0033.7332.7134.1034.4533.8433.0732.9028.58
Earnings Per Share1.731.86-0.24-0.42-0.18-0.210.210.150.23-0.39
EPS Growth-6.99%-----40%-34.78%--
Operating Cash Flow13413627.7111.8236.8835.6925.6819.6347.54-10.21
Capital Expenditures-27.23115-17.51-11.91-17.03-11.24-22.50-27.60-21.14-10.48
Free Cash Flow10725110.20-0.0919.8524.453.18-7.9726.41-20.69
Cash & Equivalents52.7843.7036.091701922049.3614.8661.336.79
Total Debt1121083971441481435.5710.9548.2880.05
Net Cash / Debt-59.53-63.87-36125.1743.6260.943.793.9113.06-73.27
Assets911806935388407447271242279215
Liabilities35138170818818820247.7142.3293.51102
Book Value560426227201219245224200185113
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Quidel Corporation
Country United States
Employees 1,250
CEO Douglas C. Bryant

Stock Information

Ticker Symbol QDEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: QDEL

Description

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.